CESALATAMIG
UNII Z2GU8Y73TK

Substance Identification & Data

This profile provides standardized clinical and technical data for Cesalatamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Z2GU8Y73TK.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3082356-04-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

Z2GU8Y73TK

CAS Registry Number

3082356-04-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CESALATAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

14085

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Cesalatamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cesalatamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

Cesalatamig

Immunoglobulin G1, bispecific, [237-alanine,238-alanine,240-alanine], anti-(human vascular endothelial growth factor) (human-Mus musculus monoclonal AI-011 γ1-chain) fusion protein with peptide linker (GGGGS)3 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus monoclonal AI-025 single-chain variable region VH-(GGGGS)4-VL), disulfide with human-Mus musculus monoclonal AI-011 κ-chain, dimer

cesalatamig [INN]

heavy chain H-gamma1 anti-VEGFA -15mer -scFvhk anti-PDCD1 (H) (1-711) [H-gamma1 anti-VEGFA (1-450) [VH Musmus/Homsap (Mus musculus IGHV9-3-1*01 (87.6%) -(IGHD) -IGHJ1*01 (94.1%)/Homo sapiens IGHV7-4-1*02 (73.2%) -(IGHD) -IGHJ3*01 (85.7%) Q120>A (112), M123>T (115), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*01v, G1m17,1>G1m3,1 CH1 R120, CH3 D12, L14, 6-G1v14-1 CH2 A1.3, A1.2, A1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238), G1>A (240) (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)] -15-mer tris (tetraglycyl-seryl) linker (451-465) -scFvhk anti-PDCD1, 11-scFv-v1 VH C49, V-KAPPA C120 (466-711) [VH (Homo sapiens IGHV3-23*04 (91.7%) -(IGHD) -IGHJ4*01 (92.3%) G49>C (509), L123>S (578), CDR-IMGT [8.8.11] (491-498.516-523.562-572)) (466-583) -20-mer tetrakis(tetraglycyl-seryl) linker (584-603) -V-KAPPA (Homo sapiens IGKV1-9*01 (87.4 %) -IGKJ2*02 (90.9%) Q120>C (703), CDR-IMGT [6.3.9] (630-635.653-655.692-700)) (604-711)]]; (223-219')-disulfide with light chain L-kappa anti-VEGFA (L') (1'-219') [V-KAPPA Musmus/Homsap (Mus musculus IGKV8-21*01 (92.0%) -IGKJ2*01 (91.7%) K123>N (108')/Homo sapiens IGKV4-1*01 (86.9%) -IGKJ2*01 (83.3%) Q120>G (105'), K123>N (108'), CDR-IMGT [12.3.8] (27'-38'.56'-58'.95'-102')) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (158'), V101 (196')) (113'-219')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa

immunoglobulin (H-gamma1-scFvhk_L-kappa) dimer, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)] and anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody (cesalatamig)

External Clinical & Regulatory Resources

Previous UNIIZ2GJT3JHC8

Next UNIIZ2H2TBF6S1